Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 10/20 | 0.43 |
| ▸ | CSF1R | P07333 | 3/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 3/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30264799 | 1.00 | ENPP1 (0.63) | ENPP1KDRFLT1PDE1BEGFR | |
| SCHEMBL23501083 | 0.93 | ENPP1 (0.63) | ENPP1KDRFLT1PDE1BEGFR | |
| SCHEMBL29359187 | 0.86 | ENPP1 (0.81) | ENPP1KDRFLT1PDE1BEGFR | |
| SCHEMBL364049 | 0.86 | ENPP1 (0.81) | ENPP1KDRFLT1PDE1BEGFR | |
| Hydrochloric Acid SCHEMBL3526531 | 0.84 | ENPP1 (0.79) | ENPP1KDRFLT1PDE1BEGFR | |
| SCHEMBL856586 | 0.83 | ENPP1 (0.67) | ENPP1KDRFLT1PDE1BEGFR | |
| SCHEMBL10121522 | 0.81 | ENPP1 (0.65) | ENPP1KDRFLT1PDE1BEGFR | |
| SCHEMBL21614043 | 0.80 | RET (0.43) | ENPP1KDRFLT1EGFRRIPK2 | |
| SCHEMBL666884 | 0.80 | ENPP1 (0.63) | ENPP1KDREGFRRAF1RET | |
| SCHEMBL24008957 | 0.80 | ENPP1 (0.63) | ENPP1KDRFLT1EGFRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-4392423-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | Arthrosi Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024059169-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023028054-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-21 | — | — | US | disclosed |
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-21 | — | — | US | disclosed |
| WO-2020043122-A1 | QUINAZOLINE DERIVATIVES AS RIP2 KINASE INHIBITOR | 南京明德新药研发有限公司 | 2020-03-05 | — | — | WO | disclosed |
| EP-3323819-B1 | COMBINATIONS OF RIP2 KINASE INHIBITOR PRODRUG 2-((4-(BENZO[D]THIAZOL-5-YLAMINO)-6-(TERT. -BUTYLSULFONYL)QUINAZOLIN-7-YL)OXY)ETHYL DIHYDROGEN PHOSPHATE WITH OTHER THERAPEUTIC AGENTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-02-26 | — | — | EP | disclosed |
| EP-3323819-B1 | COMBINATIONS OF RIP2 KINASE INHIBITOR PRODRUG 2-((4-(BENZO[D]THIAZOL-5-YLAMINO)-6-(TERT. -BUTYLSULFONYL)QUINAZOLIN-7-YL)OXY)ETHYL DIHYDROGEN PHOSPHATE WITH OTHER THERAPEUTIC AGENTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-02-26 | — | — | EP | disclosed |
| WO-2020007219-A1 | CRYSTALLINE FORM OF EGFR INHIBITOR AND PREPARATION METHOD THEREFOR | 南京明德新药研发有限公司 | 2020-01-09 | — | — | WO | disclosed |
| WO-2014043446-A1 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2014-03-20 | — | — | WO | disclosed |
| WO-2014043446-A1 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2014-03-20 | — | — | WO | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2013025958-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-21 | — | — | WO | disclosed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | disclosed |
| WO-2012068096-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | ENPP1 3408/4885KDR 2561/4885FLT1 3749/4885 |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | ENPP1 2077/4885KDR 226/4885FLT1 528/4885 |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | NQO2, PRMT7, QDPR | ENPP1 4242/4885KDR 2042/4885FLT1 2740/4885 |
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | ABL1, MAP3K3, MAP4K2 | ENPP1 3342/4885KDR 497/4885FLT1 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.